关注
Klaus Brasso
Klaus Brasso
Copenhagen Prostate Cancer Center, Rigshospitalet.
在 regionh.dk 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
CC Parker, NW Clarke, AD Cook, HG Kynaston, PM Petersen, C Catton, ...
The Lancet 396 (10260), 1413-1421, 2020
2992020
Active surveillance for clinically localized prostate cancer––A systematic review
FB Thomsen, K Brasso, LH Klotz, MA Røder, KD Berg, P Iversen
Journal of surgical oncology 109 (8), 830-835, 2014
2482014
Validation of the self‐administered Danish Prostatic Symptom Score (DAN‐PSS‐1) system for use in benign prostatic hyperplasia
BJ Hansen, H Flyger, K Brasso, J Schou, J Nordling, JT Andersen, ...
British journal of urology 76 (4), 451-458, 1995
1891995
Socioeconomic position and participation in colorectal cancer screening
BL Frederiksen, T Jørgensen, K Brasso, I Holten, M Osler
British journal of cancer 103 (10), 1496-1501, 2010
1512010
Prognostic value of PINP, bone alkaline phosphatase, CTX‐I, and YKL‐40 in patients with metastatic prostate carcinoma
K Brasso, IJ Christensen, JS Johansen, B Teisner, P Garnero, PA Price, ...
The Prostate 66 (5), 503-513, 2006
1412006
Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis
K Brasso, FB Thomsen, AJ Schrader, SC Schmid, D Lorente, M Retz, ...
European urology 68 (2), 317-324, 2015
1342015
Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis
B Malling, MA Røder, K Brasso, J Forman, M Taudorf, L Lönn
European radiology 29, 287-298, 2019
1312019
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ...
The Lancet Oncology 23 (3), 362-373, 2022
1272022
Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy
J Uth, T Hornstrup, JF Schmidt, JF Christensen, C Frandsen, ...
Scandinavian journal of medicine & science in sports 24, 105-112, 2014
1202014
First-in-human uPAR PET: imaging of cancer aggressiveness
M Persson, D Skovgaard, M Brandt-Larsen, C Christensen, J Madsen, ...
Theranostics 5 (12), 1303, 2015
1092015
ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer
KD Berg, B Vainer, FB Thomsen, MA Røder, TA Gerds, BG Toft, K Brasso, ...
European urology 66 (5), 851-860, 2014
1082014
Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study
T Steuber, KD Berg, MA Røder, K Brasso, P Iversen, H Huland, A Tiebel, ...
European urology focus 3 (6), 646-649, 2017
1002017
Determinants of participation in colorectal cancer screening with faecal occult blood testing
M von Euler-Chelpin, K Brasso, E Lynge
Journal of public health 32 (3), 395-405, 2010
922010
Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow …
J Uth, T Hornstrup, JF Christensen, KB Christensen, NR Jørgensen, ...
Osteoporosis International 27, 1507-1518, 2016
882016
Postdiagnosis statin use and mortality in Danish patients with prostate cancer
SB Larsen, C Dehlendorff, C Skriver, SO Dalton, CG Jespersen, M Borre, ...
Journal of Clinical Oncology 35 (29), 3290-3297, 2017
802017
Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—A population‐based analysis of 2 national cohorts
JT Helgstrand, MA Røder, N Klemann, BG Toft, DY Lichtensztajn, ...
Cancer 124 (14), 2931-2938, 2018
742018
Short-term morbidity and mortality following radical cystectomy: a systematic review
SL Maibom, UN Joensen, AM Poulsen, H Kehlet, K Brasso, MA Røder
BMJ open 11 (4), e043266, 2021
732021
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
FB Thomsen, MA Røder, P Rathenborg, K Brasso, M Borre, P Iversen
Scandinavian journal of urology 48 (3), 268-275, 2014
732014
Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival
JS Johansen, K Brasso, P Iversen, B Teisner, P Garnero, PA Price, ...
Clinical cancer research 13 (11), 3244-3249, 2007
732007
Safety, dosimetry, and tumor detection ability of 68Ga-NOTA-AE105: first-in-human study of a novel radioligand for uPAR PET imaging
D Skovgaard, M Persson, M Brandt-Larsen, C Christensen, J Madsen, ...
Journal of Nuclear Medicine 58 (3), 379-386, 2017
712017
系统目前无法执行此操作,请稍后再试。
文章 1–20